| Accession |
PRJCA008885 |
| Title |
NFS-01-101 (Phase I & II) |
| Relevance |
Medical |
| Data types |
Sequencing of human mitochondrial genome
|
| Organisms |
Homo sapiens
|
| Description |
The objective of this clinical study is to select the optimal dose and evaluate the safety and efficacy of NR082 in treatment of LHON caused by mitochondrial ND4 gene mutation. |
| Sample scope |
Multiisolate |
| Release date |
2024-03-29 |
| Data provider |
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Wuhan Neurophth Biotechnology Limited Company
|
clinical trial
|
NA
|
|
|
|
| Submitter |
MA
CHAO
MING (chaoming.ma@neurophth.com)
|
| Organization |
Wuhan Neuropohth Biotechnology Limited Company |
| Submission date |
2022-03-29 |
